05 +/− 18.8, 2.57 +/− 18.1 and −0.025 +/− 21.6 in
three groups, respectively. The difference significant in CGN (p = 0.006, paired t-test), but not in DN or nephrosclerosis, indicating that ESRD patients with CGN have younger arterial system than their actual age, by 9 years in average. https://www.selleckchem.com/products/dabrafenib-gsk2118436.html Conclusion: In CGN-based ESRD patiets, the arterial stiffness is preserved, but not in other ESRD patients. The reasons for their having relatively young artery system seem to be less affected their vasculature from systemic high blood pressure or glucose intolerance, and furthermore, early prescription of renin angiotensin system blockers in such clinical situation. CHEN CHIU-YUEH1, CHEN SZU-CHIA2, CHANG JER-MING2, CHEN HUNG-CHUN2 1Department of Nursing, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University; 2Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung,
Taiwan Introduction: Atrial high throughput screening assay fibrillation (AF) and arterial stiffness shared several risk factors and the two diseases often coexisted. However, the prognostic value of arterial stiffness remained uncertain in chronic kidney disease (CKD) patients with AF. We evaluated whether brachial-ankle pulse wave velocity (baPWV), a marker of arterial stiffness, predicted cardiovascular events and had significant additional prognostic value
over conventional clinical and echocariographic parameters in CKD patients with AF. Methods: This study enrolled 89 persistent AF CKD patients. Arterial stiffness was assessed by baPWV. Cardiovascular events were defined as cardiovascular death, nonfatal stroke and hospitalization for heart failure. The relative cardiovascular events risk was analyzed by Cox-regression methods. Results: During a median 15.1-month follow-up, there were 21 (23.6%) cardiovascular events. The baPWV emerged as a predictor acetylcholine of cardiovascular events (hazard ratio [HR]: 1.007; 95% confidence interval [CI]: 1.001 to 1.014; P = 0.028) in unadjusted model, and in the multivariable model adjusting for demographic, clinical, biochemical, medications and echocardiographic parameters (adjusted HR, 1.025; 95% CI: 1.008 to 1.042; P = 0.003). Conclusion: In CKD patients with AF, baPWV was a predictor of cardiovascular events. Hence, baPWV should be assessed in AF patients for additional prognostication.